NFL Biosciences S.A.
ALNFL.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €19 | €12 | €10 | €13 |
| - Cash | €2 | €2 | €1 | €3 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €17 | €9 | €9 | €10 |
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | -100% | – | -100% | – |
| Gross Profit | -€0 | -€0 | -€2 | -€1 |
| % Margin | -145,963% | -28% | – | -1,360,853.8% |
| EBITDA | -€3 | -€4 | -€3 | -€1 |
| % Margin | -5,758,256.5% | -2,024.5% | – | -2,757,612.8% |
| Net Income | -€2 | -€4 | -€2 | -€1 |
| % Margin | -4,523,563% | -1,872.6% | – | -2,508,317.9% |
| EPS Diluted | -0.21 | -0.46 | -0.47 | -0.19 |
| % Growth | 54.3% | 2.1% | -147.4% | – |
| Operating Cash Flow | €0 | €0 | €0 | €0 |
| Capital Expenditures | €0 | €0 | €0 | €0 |
| Free Cash Flow | €0 | €0 | €0 | €0 |